3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
NIH
3
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
45
Sarcoma
33
Lymphoma, Large B-Cell, Diffuse
32
Neoplasms
25
Lymphoma
20
Lymphoma, Non-Hodgkin
19
Ovarian Neoplasms
17
Lymphoma, Follicular
16
Neoplasm Metastasis
12
Triple Negative Breast Neoplasms
11
Lymphoma, B-Cell
11
Endometrial Neoplasms
11
Recurrence
10
Carcinoma, Hepatocellular
8
Hodgkin Disease
7
Lymphoma, T-Cell, Peripheral
6
Hematologic Diseases
6
Sarcoma, Kaposi
5
Lymphoma, Mantle-Cell
5
Leiomyosarcoma
5
HIV Infections
5
Acquired Immunodeficiency Syndrome
5
Multiple Myeloma
4
Liposarcoma
4
Small Cell Lung Carcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, B-Cell, Marginal Zone
3
Liver Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Fallopian Tube Neoplasms
3
Interventions
dacetuzumab
7
blinatumomab
6
Rituximab
5
ibrutinib
3
Cyclophosphamide
3
venetoclax
2
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine
2
ferric carboxymaltose
2
cobomarsen
2
Vorinostat
2
Valganciclovir
2
Lutetium
2
Lenalidomide
2
Ifosfamide
2
Ganciclovir
2
Everolimus
2
Dexamethasone
2
Bortezomib
2
ruxolitinib
1
pomalidomide
1
pegaspargase
1
ficlatuzumab
1
epratuzumab
1
enzalutamide
1
durvalumab
1
denileukin diftitox
1
cirmtuzumab
1
asparaginase erwinia chrysanthemi recombinant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoproliferative Disorders
×
Doxorubicin
×
Clear all
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled